Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular coagulation and death following the ChAdOx1 nCoV-19 vaccine
Y Aladdin, H Algahtani, B Shirah - Journal of Stroke and Cerebrovascular …, 2021 - Elsevier
Y Aladdin, H Algahtani, B Shirah
Journal of Stroke and Cerebrovascular Diseases, 2021•ElsevierCoronavirus is a novel human pathogen causing fulminant respiratory syndrome (COVID-
19). Although COVID-19 is primarily a disease of the lungs with florid respiratory
manifestations, there are increasing reports of cardiovascular, musculoskeletal,
gastrointestinal, and thromboembolic complications. Developing an effective and reliable
vaccine was emergently pursued to control the catastrophic spread of the global pandemic.
We report a fatal case of vaccine-induced immune thrombotic thrombocytopenia (VITT) after …
19). Although COVID-19 is primarily a disease of the lungs with florid respiratory
manifestations, there are increasing reports of cardiovascular, musculoskeletal,
gastrointestinal, and thromboembolic complications. Developing an effective and reliable
vaccine was emergently pursued to control the catastrophic spread of the global pandemic.
We report a fatal case of vaccine-induced immune thrombotic thrombocytopenia (VITT) after …
Abstract
Coronavirus is a novel human pathogen causing fulminant respiratory syndrome (COVID-19). Although COVID-19 is primarily a disease of the lungs with florid respiratory manifestations, there are increasing reports of cardiovascular, musculoskeletal, gastrointestinal, and thromboembolic complications. Developing an effective and reliable vaccine was emergently pursued to control the catastrophic spread of the global pandemic. We report a fatal case of vaccine-induced immune thrombotic thrombocytopenia (VITT) after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. We attribute this fatal thrombotic condition to the vaccine due to the remarkable temporal relationship. The proposed mechanism of VITT is production of rogue antibodies against platelet factor-4 resulting in massive platelet aggregation. Healthcare providers should be aware of the possibility of such fatal complication, and the vaccine recipients should be warned about the symptoms of VITT.
Elsevier